Closing the Chapter on a Booming Year of Dermatology

Image Credit: © ronstik - stock.adobe.com

The end of the year signals a time for reflection, new beginnings, and future plans. The field of dermatology witnessed prominent FDA approvals to propel innovations, such as lebrikizumab for moderate to severe atopic dermatitis, nemolizumab for prurigo nodularis, deuruxolitinib for severe alopecia areata, roflumilast cream 0.15% for atopic dermatitis in young patients, sofpironium for primary axillary hyperhidrosis, the tralokinumab autoinjector for moderate to severe atopic dermatitis, and more. If 2025 is anything like 2024, it will be another buzzing year in dermatology.

Highlighting the important advancements of dermatology in 2024 would not be possible without Dermatology Times’ quarterly editors in chief: Christopher Bunick, MD, PhD; Aaron Farberg, MD; Shanna Miranti, MPAS, PA-C; and Raj Chovatiya, MD, PhD, MSCI. Dermatology Times extends its sincerest gratitude for their dedication to education through their involvement in writing, interviews, meetings, networking, and more.

To honor their areas of expertise, each editor in chief highlighted key areas of advancements in 2024 in acne, atopic dermatitis, psoriasis, and skin cancer.

Bunick discussed transformative advances in atopic dermatitis and psoriasis care, emphasizing the adoption of minimal disease activity as a new standard, driven by innovative systemic therapies and treatment paradigms.

Farberg highlighted significant advancements in gene expression profile testing for cutaneous melanoma, with a focus on its role in informing sentinel lymph node biopsy decision-making.

Miranti reflected on advances in acne treatment, particularly the success of combination therapies such as clindamycin, adapalene, and benzoyl peroxide gel (Cabtreo), as well as acne guidelines, celebrating the growing arsenal of effective dermatologic therapies.

Chovatiya reviewed significant advancements in atopic dermatitis, including new approvals such as lebrikizumab, promising clinical trial data for treatments such as nemolizumab and roflumilast, and insights into long-term safety, efficacy, and personalized therapy approaches.

Dermatology Times’ editors in chief are continually revolutionizing the field of dermatology through their commitment to patients, peers, clinical research, and industry advancements. This month’s cover feature weaves together their expert insights to close out a breakthrough year in dermatology.

As always, Dermatology Times provides our readers with the most up-to-date clinical content, from innovative studies and FDA approvals to exclusive interviews and expert insights. Stay informed with the latest data and subscribe to Dermatology Times’ e-newsletters; follow us on Facebook, LinkedIn, and X (formerly Twitter); and email us with ideas or contributions at DTEditor@mmhgroup.com.

Cheers to 2025!